Supplementary subscription undertakings by transfer of subscription rights

        Print
| Source: NeuroVive Pharmaceutical AB
One of NeuroVive’s largest shareholders, Baulos Capital (formerly Private
Placement Sprl) and Dr. Guo Weicheng, co-founder of Sihuan Pharmaceuticals (the
company’s partner in China) have undertaken to subscribe for both their
participating interests in NeuroVive’s current right share issue.
Additionally, Maas Biolab LLC, NeuroVive’s largest shareholder, has undertaken
to donate for free and transfer a total of approx. 2 million subscription rights
to Baulos Capital and Dr. Guo Weicheng, which Baulos Capital and Dr. Guo
Weicheng have undertaken to subscribe for.

Overall, this means a commitment by Baulos Capital to subscribe for 595,000
shares, or approx. SEK 8.3 m, and by Dr. Guo Weicheng a commitment to subscribe
for 358,250 shares, or approx. SEK 5 m in the rights share issue.

The subscription period for NeuroVive’s current rights share issue continues
until 27 January 2014 and is open to current and new investors and shareholders.
More information about the right share issue including video interviews and
application forms are available at http://neurovive.irportalen.se/?lang=en

About NeuroVive
NeuroVive Pharmaceutical AB (publ) is a leading mitochondrial medicine company
that is developing a portfolio of products to treat acute cardiovascular and
neurological conditions through mitochondrial protection. These conditions are
characterized by substantial patient need and the absence of approved
pharmaceutical treatments at present. NeuroVive’s products, CicloMulsion®
(myocardial infarction) and NeuroSTAT® (traumatic brain injury), are currently
in phase III and phase II studies respectively. NeuroVive’s research also
encompasses products for the treatment of antiviral indications (Hepatitis B/C),
injuries to brain cells in stroke and candidate drugs providing neuroprotection
and energy regulation in mitochondrial disease. NeuroVive is listed on NASDAQ
OMX Stockholm.

For Investor Relations and media questions, please contact:
Ingmar Rentzhog, Laika Consulting, tel: +46 (0)46 275 62 21 or ir@neurovive.se
It is also possible to arrange an interview with NeuroVive’s CEO Mikael
Brönnegård at the above contact.

NeuroVive Pharmaceutical AB (publ)

Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard), Fax: + 46 (0)46 888 83 48
info@neurovive.se, www.neurovive.se

NeuroVive Pharmaceutical AB (publ) is required to publish the information in
this press release under The Swedish Securities Market Act. The information was
submitted for publication on 23 January 2014, at 16:20 CEST